1-2 of 2
Peter Kiessling
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia

Tadeusz Robak, MD, Maciej Kaźmierczak, Isidro Jarque, Vasile Musteata, MD PhD, Jacek Trelinski, Nichola Cooper, MD MRCP, Peter Kiessling, Ute Massow, Franz Woltering, Rose Snipes, Juan Ke, Grant Langdon, Birgit Haier, James B. Bussel, MD, Stephen Jolles
Journal: Blood
Blood (2019) 134 (Supplement_1): 897.
https://doi.org/10.1182/blood-2019-129839
Published: 2019
Journal Articles

Phase II, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis

Tadeusz Robak, Isidro Jarque, Vasile Musteata, Peter Kiessling, Ute Massow, James Higginson, Rose Snipes, Stephen Jolles
Journal: Blood
Blood (2017) 130 (Supplement 1): 15.
https://doi.org/10.1182/blood.V130.Suppl_1.15.15
Published: 2017